R Lee Mosley

List of Publications by Year
in descending order

77 papers	5,618 citations	109264 35 h-index	95218 68 g-index
78 all docs	78 docs citations	78 times ranked	6148 citing authors

#	Article	IF	Citations
1	Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinsonâ€™s Disease. Journal of Immunology, 2010, 184, 2261-2271.	0.4	346
2	Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinsonâ€™s disease. Journal of Leukocyte Biology, 2007, 82, 1083-1094.	1.5	323
3	Nitrated Î±â€“Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. PLoS ONE, 2008, 3, e1376.	1.1	311
4	Neuroinflammation, oxidative stress, and the pathogenesis of Parkinsonâ€™s disease. Clinical Neuroscience Research, 2006, 6, 261-281.	0.8	305
5	Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9435-9440.	3.3	299
6	CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinsonâ€™s Disease. Journal of NeuroImmune Pharmacology, 2012, 7, 927-938.	2.1	255
7	Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 2006, 108, 2827-2835.	0.6	241
8	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nature Communications, 2019, 10, 2753.	5.8	222
9	Inflammation and Adaptive Immunity in Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009381-a009381.	2.9	221
10	Nitrated alphaâ€synucleinâ€activated microglial profiling for Parkinsonâ€™s disease. Journal of Neurochemistry, 2008, 104, 1504-1525.	2.1	195
11	A Macrophageâ€“Nanozyme Delivery System for Parkinson's Disease. Bioconjugate Chemistry, 2007, 18, 1498-1506.	1.8	177
12	Nitrated Î±-Synuclein-Induced Alterations in Microglial Immunity Are Regulated by CD4+ T Cell Subsets. Journal of Immunology, 2009, 182, 4137-4149.	0.4	177
13	Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice. PLoS ONE, 2008, 3, e2740.	1.1	174
14	Macrophage delivery of therapeutic nanozymes in a murine model of Parkinsonâ€™s disease. Nanomedicine, 2010, 5, 379-396.	1.7	154
15	NanoART synthesis, characterization, uptake, release and toxicology for human monocyteâ€“macrophage drug delivery. Nanomedicine, 2009, 4, 903-917.	1.7	116
16	Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease. Antioxidants and Redox Signaling, 2009, 11, 2151-2166.	2.5	114
17	Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Journal of Controlled Release, 2011, 150, 204-211.	4.8	107
18	Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 751-767.	1.7	98

#	Article	IF	Citations
19	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinsonâ€™s disease trial. Npj Parkinson's Disease, 2017, 3, 10.	2.5	98
20	A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology, 2017, 14, 17.	0.9	94
21	GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. Journal of Neuroimmunology, 2013, 265, 1-10.	1.1	90
22	Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells. Journal of Proteome Research, 2009, 8, 3497-3511.	1.8	78
23	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 2018, 151, 53-65.	5.7	77
24	Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease. Journal of Neuroscience, 2005, 25, 1691-1700.	1.7	76
25	Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. Journal of Neuroscience, 2015, 35, 16463-16478.	1.7	68
26	A year-long extended release nanoformulated cabotegravir prodrug. Nature Materials, 2020, 19, 910-920.	13.3	66
27	Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. Translational Neurodegeneration, 2014, 3, 25.	3.6	65
28	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1â€“Infected Human Peripheral Blood Lymphocyteâ€“Reconstituted Mice. Journal of Infectious Diseases, 2012, 206, 1577-1588.	1.9	62
29	Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Molecular Neurodegeneration, 2020, 15, 32.	4.4	57
30	Immunotherapy for Parkinsonâ€™s disease. Neurobiology of Disease, 2020, 137, 104760.	2.1	57
31	CD 4+ T cells in the pathobiology of neurodegenerative disorders. Journal of Neuroimmunology, 2009, 211, 3-15.	1.1	48
32	CD4+ effector T cells accelerate Alzheimerâ€™s disease in mice. Journal of Neuroinflammation, 2021, 18, 272.	3.1	48
33	Proteomic Modeling for HIV-1 Infected Microglia-Astrocyte Crosstalk. PLoS ONE, 2008, 3, e2507.	1.1	46
34	Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinsonâ€™s disease. Molecular Neurodegeneration, 2018, 13, 26.	4.4	39
35	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. International Journal of Nanomedicine, 2011, 6, 3393.	3.3	37
36	Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. Journal of Neurochemistry, 2010, 114, 1261-1276.	2.1	36

#	Article	IF	Citations
37	A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders. Journal of NeuroImmune Pharmacology, 2015, 10, 645-650.	2.1	36
38	URMC-099 facilitates amyloid-Î² clearance in a murine model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2018, 15, 137.	3.1	36
39	A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinsonâ€™s Disease. Frontiers in Cellular Neuroscience, 2019, 13, 421.	1.8	32
40	Granulocyte-Macrophage Colony Stimulating Factor Exerts Protective and Immunomodulatory Effects in Cortical Trauma. Journal of Neuroimmunology, 2015, 278, 162-173.	1.1	30
41	Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitisâ˜†. Journal of Neuroimmunology, 2011, 230, 33-41.	1.1	28
42	Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions. Frontiers in Immunology, 2021, 12, 741502.	2.2	28
43	Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials, 2018, 185, 174-193.	5.7	27
44	Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics, 2020, 10, 630-656.	4.6	27
45	Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease. Biomaterials, 2021, 272, 120786.	5.7	26
46	Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Experimental Neurology, 2010, 222, 1-5.	2.0	25
47	Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics, 2016, 13, 635-646.	2.1	24
48	Comparison of the Hematopoietic Activity of flt-3 Ligand and Granulocyte-Macrophage Colony-Stimulating Factor Acting Alone or in Combination. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 711-720.	1.8	23
49	Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Research, 2015, 120, 85-88.	1.9	23
50	Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease. EBioMedicine, 2021, 67, 103380.	2.7	23
51	CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination. EBioMedicine, 2021, 73, 103678.	2.7	23
52	T cells and Parkinson's disease. Lancet Neurology, The, 2017, 16, 769-771.	4.9	22
53	Multidimensional protein fractionation using ProteomeLab PF 2Dâ„¢ for profiling amyotrophic lateral sclerosis immunity: A preliminary report. Proteome Science, 2008, 6, 26.	0.7	20
54	Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology, 2021, 18, 13.	0.9	20

#	Article	IF	Citations
55	Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 235-242.	2.3	19
56	Neuroprotective Activities of Long-Acting Granulocyteâ€“Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice. Neurotherapeutics, 2020, 17, 1861-1877.	2.1	17
57	Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis. ACS Chemical Neuroscience, 2022, 13, 1232-1244.	1.7	16
58	Flt3 ligand and conjugation to IL-1Î² peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine. Vaccine, 2002, 20, 2358-2368.	1.7	14
59	Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS ONE, 2015, 10, e0145966.	1.1	13
60	Role of the EHD Family of Endocytic Recycling Regulators for TCR Recycling and T Cell Function. Journal of Immunology, 2018, 200, 483-499.	0.4	13
61	Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Journal of NeuroVirology, 2018, 24, 398-410.	1.0	11
62	Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease. Clinical and Translational Medicine, 2022, 12, .	1.7	11
63	Flt3 ligand augmentation of T cell mitogenesis and expansion of type 1 effector/memory T cells. International Immunopharmacology, 2002, 2, 925-940.	1.7	10
64	Development of an extended half-life GM-CSF fusion protein for Parkinson's disease. Journal of Controlled Release, 2022, 348, 951-965.	4.8	10
65	Adaptive Immunity in Neurodegenerative and Neuropsychological Disorders. Journal of NeuroImmune Pharmacology, 2015, 10, 522-527.	2.1	9
66	The Immunopathobiology of SARS-CoV-2 Infection. FEMS Microbiology Reviews, 2021, 45, .	3.9	9
67	Prodrug Therapies for Infectious and Neurodegenerative Diseases. Pharmaceutics, 2022, 14, 518.	2.0	3
68	Interleukin-2 expands neuroprotective regulatory T cells in Parkinsonâ€™s disease. , 2022, .		3
69	Neuroimaging and Proteomic Tracking of Neurodegeneration in MPTPâ€Treated Mice. Annals of the New York Academy of Sciences, 2003, 991, 319-321.	1.8	2
70	Therapeutic Strategies in Neurodegenerative Diseases. , 2017, , 681-711.		2
71	Immunotherapies for Movement Disorders: Parkinsonâ€™s Disease and Amyotrophic Lateral Sclerosis. , 2017, , 767-797.		1
72	Innate and Adaptive Immune-Mediated Neuroinflammation and Neurodegeneration in Parkinsonâ€™s Disease. , 2014, , 119-142.		1

#	Article	IF	Citations
73	Neuroprotective Activities of CD4+CD25+ Regulatory T Cells. NeuroImmune Biology, 2010, 9, 197-210.	0.2	0
74	Glatiramer Acetate. , 2018, , .		0
75	X-Ray, Positron Emission, and Single Photon Emission Tomographic Bioimaging. Springer Protocols, 2014, , 271-292.	0.1	0
76	Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases. , 2020, , 335-370.		0
77	CD4+ T cell effector activities accelerate Alzheimer's disease pathologies.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052738.	0.4	0